Clinical trial
Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan
NCT02616380 is registered in ClinicalTrials.gov with AbbVie as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Real-World Outcome of Adalimumab on Rheumatoid Arthritis Patients in Taiwan
- Lead sponsor
- AbbVie
- Phase
- Observational
- Overall status
- Completed
- Start date
- November 5, 2015
- Completion date
- November 23, 2017
- Enrollment
- 100 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.
rheumatoid arthritis